Galera Therapeutics

Galera Therapeutics develops novel therapeutics that reduce severe side effects of radiation therapy in cancer patients. The lead molecule GC4419 has demonstrated efficacy in a phase IIb study in patients with head and neck cancer and has been granted Fast Track and Breakthrough Therapy designations by the U.S. FDA.